FDA Grants Accelerated Approval To Lilly's Retevmo For Pediatric Patients With Advanced Thyroid Cancer And RET Gene Fusion; First Targeted Therapy Approved For Patients Under 12 With RET Alterations
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted accelerated approval to Eli Lilly's Retevmo for pediatric patients with advanced thyroid cancer and RET gene fusion. This marks the first targeted therapy approved for patients under 12 with RET alterations.
May 29, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Retevmo has received FDA accelerated approval for pediatric patients with advanced thyroid cancer and RET gene fusion, marking a significant milestone as the first targeted therapy for patients under 12 with RET alterations.
The FDA's accelerated approval of Retevmo for pediatric patients with advanced thyroid cancer and RET gene fusion is a significant development for Eli Lilly. This approval not only expands the drug's market but also positions Eli Lilly as a leader in targeted therapies for rare pediatric conditions. The news is likely to positively impact Eli Lilly's stock price in the short term due to the potential for increased sales and market confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100